BioCryst Pharmaceuticals · North Carolina Remote, Country not listed
· Posted 2026-07-29
· 7+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
SrSystemsEngineer
BioCryst Pharmaceuticals · US_North Carolina_Remote, Country not listed
· Posted 2026-07-23
· 3+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
MSLSrPiedmontregion
BioCryst Pharmaceuticals · US_North Carolina_Remote, Country not listed
· Posted 2026-07-15
· 10+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics. Our global head
DirectorDrugProductDevelopment
BioCryst Pharmaceuticals · US_North Carolina_Remote, Country not listed
· Posted 2026-06-29
· 5+ years
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics, led by the effo
SrTranslationalModeling
BioCryst Pharmaceuticals · US_North Carolina_Remote, Country not listed
· Posted 2026-06-29
COMPANY: At BioCryst, we share a deep commitment to improving the lives of people living with hereditary angioedema (HAE) and other rare diseases. We leverage our expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and injectable protein therapeutics, led by the effo
DirectorQualityControl